S6 Ep42: Jabbour Highlights New Data With Asciminib and Ponatinib in CML
OncLive® On Air
00:00
Why Asciminib Wasn't Compared to Ponatinib
Elias Jabbour notes ASCEMBL compared asciminib to bosutinib and that head-to-head data versus ponatinib are not yet available.
Play episode from 04:34
Transcript
